2458 related articles for article (PubMed ID: 21391729)
21. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
22. Intensive statin therapy for Indians: Part-I. Benefits.
Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
[TBL] [Abstract][Full Text] [Related]
23. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
24. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
25. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
Robinson JG; Smith B; Maheshwari N; Schrott H
J Am Coll Cardiol; 2005 Nov; 46(10):1855-62. PubMed ID: 16286171
[TBL] [Abstract][Full Text] [Related]
26. Statin therapy and stroke prevention: what was known, what is new and what is next?
Mazighi M; Lavallée PC; Labreuche J; Amarenco P
Curr Opin Lipidol; 2007 Dec; 18(6):622-5. PubMed ID: 17993806
[TBL] [Abstract][Full Text] [Related]
27. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
Packard C
Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
[TBL] [Abstract][Full Text] [Related]
28. Pleiotropic effects and cholesterol-lowering therapy.
Shaw SM; Fildes JE; Yonan N; Williams SG
Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
[TBL] [Abstract][Full Text] [Related]
29. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
30. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
[TBL] [Abstract][Full Text] [Related]
33. [Clinical trials with rosuvastatin: efficacy and safety of its use].
Schweiger C
Ital Heart J; 2003 Dec; 4 Suppl 7():33S-46S. PubMed ID: 14983745
[TBL] [Abstract][Full Text] [Related]
34. Exploring new indications for statins beyond atherosclerosis: Successes and setbacks.
Waters DD
J Cardiol; 2010 Mar; 55(2):155-62. PubMed ID: 20206067
[TBL] [Abstract][Full Text] [Related]
35. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
37. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
38. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
40. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
